Navigation Links
From microscope to stethoscope: The MUHC's public lecture series begins its 2nd season tomorrow
Date:10/2/2007

Montreal, October 2nd, 2007 - From Microscope to Stethoscope, the distinguished public lecture series organized by the Research Institute of the McGill University Health Centre (MUHC), is embarking on its second season tomorrow.

For this opening conference, Dr. Vassilios Papadopoulos, Director of the Research Institute of the MUHC, will be sharing the hope that his current research may bring to patients suffering from Alzheimers disease. Alzheimers disease is one of the most devastating neurodegenerative pathologies, for both patients and families; unfortunately its origins are still a mystery, explains Dr Papadopoulos. His latest laboratory findings could lead to remarkable therapeutic advances and relieve the difficulties doctors currently have in terms of diagnosis and treatment.

The second lecture will be given on Monday, November 7, 2007, by Dr. Lawrence Rosenberg, a world expert in diabetes, and the third one will be by Dr. Ronald Olivenstein, MUHC Asthma Clinic Director, on Wednesday, December 3, 2007.

"Again this year, three of our most brilliant researchers invite you on a journey into a possible future, when current research has already turned into innovative treatments for patients, declared Dr. Arthur T. Porter, Director General of the MUHC. These lectures will give you a direct look at the intellectual vitality that fills our research laboratories and the enormous impact of this work on our daily lives.

The lectures will take place at the Montreal General Hospital in Livingston Hall (Rom L6-500) starting at 7:30 p.m. Admission is free and anyone interested is welcome.

The speakers will take questions from audience members during a discussion period following each lecture.


'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-934-1934
McGill University Health Centre
Source:Eurekalert

Page: 1

Related medicine news :

1. Controversial deal on public access of the human genome map
2. Defibrillators In Public Places Will Help Cardiac Patients
3. WHO To Support Public Health Threats
4. Public Defibrillators Found To Improve Survival Rate
5. FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
6. WHO Steps Up To Create A Public Awareness About The Consequences Of Exposure To Radon
7. Disaster Planning Guide From Harvard Health Publications
8. India to maintain Public domain Registry database of clinical trials conducted in India.
9. Smoking Ban Believed To Enjoy Widespread Public Acceptance In Scotland
10. Evidences that Better Health Care Facility is Offered By Public Hospitals.
11. UK public misled over downgrading cannabis: Govt

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... Nov. 20 The American ...fy health care reform legislation released this we... insurance individual coverage mandate. The actuar... will minimize adverse selection stemming from mor... the bill. ,, "The individual mandate language ...
(Date:11/20/2009)..., Nov. 20 Following a recall by Un...oved from sale Shedd,s Country Crock ® Side D...ntry Crock ® Side Dishes DELUXE Four Cheese P... The following code dates and UPCs are affected: ,...UXE Cheddar Broccoli Rice 21 oz, UPC 027400218316,...
(Date:11/20/2009)....J., Nov. 20 Rates of in...peaked in late October, but the pandemic flu virus...all age groups, including the elderly, according t...NYSE: DGX ), the world,s leading provider of dia...In its most recent Quest Diagnostics Health Trends...
(Date:11/20/2009)... Nov. 20 Centene Corpo... present at the Bank of America Merrill Lynch 2009... at the Crowne Plaza Hotel Times Square in New Yor...mber 2nd at 8:30 a.m. Eastern Time. Investors and ...webcast of Centene,s presentation at: http://www....
(Date:11/20/2009)..., N.C., Nov. 20 Samuel ...redefine what it means to be "happy" during the ho...a specialty in family counseling and chair of the ..., Gladding says research shows that it is the pres...ven depression during the holidays. ,, That,s w...
Breaking Medicine News(10 mins):Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Why Holidays Don't Have To Be 'Happy' 2
... antibody drug to chemotherapy looks promising for...ding to Mayo Clinic researchers working with the N...://ncctg.mayo.edu/ ). Results of this interim anal...tients responded to treatment that included the dr...
...surgeries, researchers report , , FRIDAY,...ng rates, the number of mastectomies performed on ... Mayo Clinic now reports. , The increase coincid... at the American Society of Clinical Oncology (ASC...
... IDMI ) today announced that clinical data presen...idates will be made at the upcoming 44th,American .... Data presented,at the meeting will support impro... Presentation highlights are as follows:, L-MTP-P...
...s with metal complexes, scientists at The Wistar I...itor capable of blocking a biochemical pathway tha...d on studies in human melanoma cells, the research... of the study, to be published in the May 16 issue...
...y hospitals associated with Fox Chase Cancer Cente...een a major academic cancer center, where most new...spitals, where most care is provided, is a highly ...in Philadelphia, first established its network of ...
...edication also known by the trade name Celebrex, h...eration measurement of precancerous lesions in the... Texas M. D. Anderson Cancer Center. This finding ...is the first large randomized trial of Celebrex in...
Other Medicine News:Health News:Adding epratuzumab to standard therapy 2Health News:Mastectomies on the Increase 2Health News:Mastectomies on the Increase 3Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 2Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 3Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 2Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 3Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3
(Date:11/19/2009)..., Nov. 19 In a series of...nce, Heska Corporation (Nasdaq: HSKA ) ("Heska" o... new and improved website. The upgraded site is t...d programming to align the site with the company,s...(Logo: http://www.newscom.com/cgi-bin/prnh/20000...
(Date:11/19/2009)...., Nov. 19 The D e al...of its Most Admired Corporate Dealmakers for the s... as its Most Admired Dealmaker in pharma/biotech f...s and divestitures since January 2006. ,, Over ...portfolio with a focus on high-growth, innovation-...
(Date:11/19/2009)...., Nov. 19 Mach 7 Technologies, ...care image management solutions, and QStar Technol...ed PACS- neutral archive solution through their co...n international leader in providing digital image ...l industry. Under the agreement, Data Distributin...
Breaking Medicine Technology:Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 2Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 4NexInfo Solutions Inc Selected by Beckman Coulter to Design and Streamline Global Sales 26 Operations Planning Processes 13597 1NexInfo Solutions Inc Selected by Beckman Coulter to Design and Streamline Global Sales 26 Operations Planning Processes 13597 2NexInfo Solutions Inc Selected by Beckman Coulter to Design and Streamline Global Sales 26 Operations Planning Processes 13597 3Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 1Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 2US born Asian American women more likely to think about attempt suicide 54659 1US born Asian American women more likely to think about attempt suicide 54659 2US born Asian American women more likely to think about attempt suicide 54659 3
...nd the European Organisation for the Research and ...llow-up results from the landmark Phase III,trial ...titute of Canada,(NCIC) that showed the combinatio...les and radiation therapy significantly prolonged,...(GBM) versus radiation,treatment alone and that a ...
... 6211 for the Potential Treatment of Pa...nd MUMBAI, India, Oct. 30 Eli,Lilly and Company (...nto an,agreement with Glenmark Pharmaceuticals S.A...rmaceuticals Limited India (GPL). Under the terms,... a portfolio of transient,receptor potential vanil...
Other Medicine Technology:Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme 2Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme 3Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme 4Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme 5Lilly and Glenmark Pharmaceuticals Announce License Agreement 2Lilly and Glenmark Pharmaceuticals Announce License Agreement 3Lilly and Glenmark Pharmaceuticals Announce License Agreement 4Lilly and Glenmark Pharmaceuticals Announce License Agreement 5
...ORE-TEX Stretch Vascular Grafts have met the chall...ecognized for exceptional performance and quality,...eons worldwide. These grafts require no preclottin...and ensure utmost thrombectomy safety. The GORE-TE...
...oday's evolving techniques for vascular surgery, a... require that new, specialized types of graft be d...d biocompatible, but also available in varying siz.... GORE-TEX Vascular Graft has long been the prosth...
...ORE-TEX Vascular Grafts have met the challenges of...5 years. Recognized for exceptional performance an...owned surgeons worldwide. These grafts require no ...nfection, and assure utmost thrombectomy safety. T...
...ORE-TEX® Vascular Grafts have met the challeng...ver 25 years. Recognized for exceptional performan...f renowned surgeons worldwide. These grafts requir... of infection, and assure utmost thrombectomy safe...
Medicine Products: